Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older | Zendy

Héctor S. Izurieta | Zendy; Michael Wernecke | Zendy; Jeffrey A. Kelman | Zendy; Sarah Anne Wong | Zendy; Richard A. Forshee | Zendy; Douglas Pratt | Zendy; Yun Lu | Zendy; Qin Sun | Zendy; Christopher Jankosky | Zendy; Philip R. Krause | Zendy; Chris Worrall | Zendy; Tom MaCurdy | Zendy; Rafael Harpaz | Zendy

Open Access

Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older

Author(s) -

Héctor S. Izurieta,

Michael Wernecke,

Jeffrey A. Kelman,

Sarah Anne Wong,

Richard A. Forshee,

Douglas Pratt,

Yun Lu,

Qin Sun,

Christopher Jankosky,

Philip R. Krause,

Chris Worrall,

Tom MaCurdy,

Rafael Harpaz

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw854

Subject(s) - medicine , postherpetic neuralgia , shingles , vaccination , cohort , population , cohort study , retrospective cohort study , pediatrics , demography , surgery , immunology , environmental health , virus , sociology , neuropathic pain , pharmacology

Tens of millions of seniors are at risk of herpes zoster (HZ) and its complications. Live attenuated herpes zoster vaccine (HZV) reduces that risk, although questions regarding effectiveness and durability of protection in routine clinical practice remain. We used Medicare data to investigate HZV effectiveness (VE) and its durability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research